EWTX News and Press, Edgewise Therapeutics Inc. From 11/02/23

Edgewise Therapeutics Inc. (EWTX) is expected to report $-0.4 for Q3 2023

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present the results of nonclinical studies of EDG-7500 at the American Heart Association’s (AHA) Scientific Sessions 2023 being held in Philadelphia from N...

– Initiating new Phase 2 FOX trial in boys with Duchenne who have been previously treated with gene therapy – – Continuing dose escalation of Phase 2 LYNX trial and initiating a cohort in boys with Duchenne not currently treated with corticosteroids – ...

2023-10-03 17:29:36 ET Gainers: Edgewise Therapeutics ( NASDAQ: EWTX ) +7% . Cantaloupe ( CTLP ) +6% . Computer Programs and Systems ( CPSI ) +6% . REGENXBIO  ( RGNX ) +5% . Tandem Diabetes Care ( TNDM ) +5% . Lose...

– Company to host conference symposium to discuss its approach to protecting dystrophic muscle featuring key opinion leaders and 12-month results from the ARCH open label study of EDG-5506 in adults with Becker – Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading mus...

– GRAND CANYON is the first pivotal study of an investigational therapy for Becker – – CANYON, the initial Phase 2 cohorts, is fully enrolled – Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today ann...

– EDG-7500 is a first-in-class oral, selective, cardiac sarcomere modulator that has the potential to benefit a broad spectrum of HCM and other cardiomyopathy patients – Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, toda...

2023-08-10 10:11:44 ET Edgewise Therapeutics press release ( NASDAQ: EWTX ): Q2 Non-GAAP EPS of -$0.34. Cash, cash equivalents and marketable securities were approximately $310 million as of June 30, 2023. For further details see: Edgewise Therapeutics Non-GAAP E...

– Announced positive 12-month topline results from the ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy (Becker) – – Advancing Phase 2 trial of EDG-5506 in Becker muscular dystrophy (Becker, CANYON), which now includes a pivotal cohort call...

– Sustained positive trend in North Star Ambulatory Assessment (NSAA) scores relative to BMD natural history – – Significant decreases in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarkers associated with skeletal muscl...